These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 38915767)

  • 21. How Molecular Topology Can Help in Amyotrophic Lateral Sclerosis (ALS) Drug Development: A Revolutionary Paradigm for a Merciless Disease.
    Galvez-Llompart M; Zanni R; Garcia-Domenech R; Galvez J
    Pharmaceuticals (Basel); 2022 Jan; 15(1):. PubMed ID: 35056151
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS.
    Vieira FG; Ping Q; Moreno AJ; Kidd JD; Thompson K; Jiang B; Lincecum JM; Wang MZ; De Zutter GS; Tassinari VR; Levine B; Hatzipetros T; Gill A; Perrin S
    PLoS One; 2015; 10(8):e0135570. PubMed ID: 26288094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Teaching an old dog new tricks: serum troponin T as a biomarker in amyotrophic lateral sclerosis.
    Castro-Gomez S; Radermacher B; Tacik P; Mirandola SR; Heneka MT; Weydt P
    Brain Commun; 2021; 3(4):fcab274. PubMed ID: 34993474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current Drug Repurposing Strategies for Rare Neurodegenerative Disorders.
    Shah S; Dooms MM; Amaral-Garcia S; Igoillo-Esteve M
    Front Pharmacol; 2021; 12():768023. PubMed ID: 34992533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.
    Deeb O; Nabulsi M
    Curr Top Med Chem; 2020; 20(26):2391-2403. PubMed ID: 32972341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Remote versus face-to-face home-based exercise programme in people with amyotrophic lateral sclerosis: protocol for a randomised clinical trial.
    Souza AA; Silva STD; Pondofe KM; Resqueti VR; Melo LP; Valentim RAM; Ribeiro TS
    BMJ Open; 2022 May; 12(5):e056323. PubMed ID: 35618326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of heat shock proteins in Amyotrophic Lateral Sclerosis: The therapeutic potential of Arimoclomol.
    Kalmar B; Lu CH; Greensmith L
    Pharmacol Ther; 2014 Jan; 141(1):40-54. PubMed ID: 23978556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Network pharmacology analysis and clinical efficacy of the traditional Chinese medicine Bu-Shen-Jian-Pi. Part 3: Alleviation of hypoxia, muscle-wasting, and modulation of redox functions in amyotrophic lateral sclerosis.
    Li R; Han X; Wang Q; Wang C; Jing W; Zhang H; Wang J; Pan W
    Int J Clin Pharmacol Ther; 2024 Apr; 62(4):169-177. PubMed ID: 38431830
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drugs in clinical development for the treatment of amyotrophic lateral sclerosis.
    Martinez A; Palomo Ruiz MD; Perez DI; Gil C
    Expert Opin Investig Drugs; 2017 Apr; 26(4):403-414. PubMed ID: 28277881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I trial of repeated intrathecal autologous bone marrow-derived mesenchymal stromal cells in amyotrophic lateral sclerosis.
    Oh KW; Moon C; Kim HY; Oh SI; Park J; Lee JH; Chang IY; Kim KS; Kim SH
    Stem Cells Transl Med; 2015 Jun; 4(6):590-7. PubMed ID: 25934946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cell-based therapies for amyotrophic lateral sclerosis/motor neuron disease.
    Abdul Wahid SF; Law ZK; Ismail NA; Lai NM
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD011742. PubMed ID: 31853962
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement.
    Katyal N; Govindarajan R
    Front Neurol; 2017; 8():521. PubMed ID: 29033893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy.
    Lo Piccolo L; Umegawachi T; Yeewa R; Potikanond S; Nimlamool W; Prachayasittikul V; Gotoh Y; Yoshida H; Yamaguchi M; Jantrapirom S
    Neurotherapeutics; 2023 Sep; 20(5):1330-1346. PubMed ID: 37493896
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Protocol for a double-blind randomised placebo-controlled trial of lithium carbonate in patients with amyotrophic lateral sclerosis (LiCALS) [Eudract number: 2008-006891-31].
    Al-Chalabi A; Shaw PJ; Young CA; Morrison KE; Murphy C; Thornhill M; Kelly J; Steen IN; Leigh PN;
    BMC Neurol; 2011 Sep; 11():111. PubMed ID: 21936930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive Research on Past and Future Therapeutic Strategies Devoted to Treatment of Amyotrophic Lateral Sclerosis.
    Sever B; Ciftci H; DeMirci H; Sever H; Ocak F; Yulug B; Tateishi H; Tateishi T; Otsuka M; Fujita M; Başak AN
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DiPALS: Diaphragm Pacing in patients with Amyotrophic Lateral Sclerosis - a randomised controlled trial.
    McDermott CJ; Bradburn MJ; Maguire C; Cooper CL; Baird WO; Baxter SK; Cohen J; Cantrill H; Dixon S; Ackroyd R; Baudouin S; Bentley A; Berrisford R; Bianchi S; Bourke SC; Darlison R; Ealing J; Elliott M; Fitzgerald P; Galloway S; Hamdalla H; Hanemann CO; Hughes P; Imam I; Karat D; Leek R; Maynard N; Orrell RW; Sarela A; Stradling J; Talbot K; Taylor L; Turner M; Simonds AK; Williams T; Wedzicha W; Young C; Shaw PJ
    Health Technol Assess; 2016 Jun; 20(45):1-186. PubMed ID: 27353839
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Breaking barriers with tofersen: Enhancing therapeutic opportunities in amyotrophic lateral sclerosis.
    Saini A; Chawla PA
    Eur J Neurol; 2024 Feb; 31(2):e16140. PubMed ID: 37975798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and efficacy of arimoclomol in patients with early amyotrophic lateral sclerosis (ORARIALS-01): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
    Benatar M; Hansen T; Rom D; Geist MA; Blaettler T; Camu W; Kuzma-Kozakiewicz M; van den Berg LH; Morales RJ; Chio A; Andersen PM; Pradat PF; Lange D; Van Damme P; Mora G; Grudniak M; Elliott M; Petri S; Olney N; Ladha S; Goyal NA; Meyer T; Hanna MG; Quinn C; Genge A; Zinman L; Jabari D; Shoesmith C; Ludolph AC; Neuwirth C; Nations S; Shefner JM; Turner MR; Wuu J; Bennett R; Dang H; Sundgreen C;
    Lancet Neurol; 2024 Jul; 23(7):687-699. PubMed ID: 38782015
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing clinical trials in neurodegenerative disorders: lessons from amyotrophic lateral sclerosis.
    Gladman M; Cudkowicz M; Zinman L
    Curr Opin Neurol; 2012 Dec; 25(6):735-42. PubMed ID: 23160423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.